Don't Waste Your Money on Penny Stocks, These 2 Stocks Are Better Buys
These healthcare stocks are risky, but they offer investors much better wealth-building potential than penny stocks.
Precision BioSciences Inc(DTIL)
Nasdaq Global Select
DTIL
$11.96
$0.83
7.5%
Price as of February 26, 2021, 9:00 p.m. EST
View Interactive DTIL Charts
Interactive Chart
News & Analysis: Precision BioSciences Inc
About to Buy Penny Stocks? Look at These 2 Companies First
These healthcare stocks offer high risk and high reward, but they aren't nearly as risky as penny stocks.
These Gene-Editing Pioneers Are Making Bold Bets in Agriculture
Investors shouldn't forget that the world of biotech extends beyond biopharmaceuticals.
Did Cellectis Just Provide a Glimpse of the Future of Cellular Medicine?
The gene editing company published a proof-of-concept for "smart" immunotherapies. The idea may catch on.
This Start-up Might Be the Next Gene Editing IPO
An early-stage start-up with an improved version of CRISPR gene editing filed to go public. Investors may want to keep an eye on it.
Why International Flavors & Fragrances, Precision BioSciences, and GameStop Slumped Today
Find out why one of these stocks lost more than half its value.
No CRISPR Required: This Forgotten Gene Editing Stock Is Up 50% in 5 Weeks
Investors should remember that CRISPR isn't the only gene editing technology out there. Case in point: ARCUS.
Here's Why Shares of This Gene Editing Pioneer Are Collapsing Today
Precision BioSciences provided an expanded update from its first clinical asset. Investors weren't impressed.
Here's Why Precision BioSciences Is Soaring Today
The gene-editing company rallied investors around intriguing clinical data released earlier this month, and the rally hasn't stopped.
There's Yet Another Gene Editing Technique, but It Has 1 Glaring Problem
The media has gotten a little carried away (again) by overlooking a simple technical flaw in the latest gene editing tool.
